Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week

Trial Profile

Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabedersen (Primary) ; Lomustine; Procarbazine; Temozolomide; Vincristine
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Therapeutic Use
  • Sponsors Isarna Therapeutics; Sirna Therapeutics
  • Most Recent Events

    • 28 Dec 2022 According to an Oncotelic Inc media release, data from the trial were presented at the 12th AACR-JCA Joint Conference.
    • 02 Dec 2019 According to Oncotelic Inc media release, data from this trial was published in the oncology journals Cancer ClinicsJournal and Annals of Hematology and Oncology Research.Also published was a peer-reviewed research article in the prestigious oncology journal Cancers.
    • 18 Nov 2019 According to a Mateon Therapeutics media release, data from this study will be presented the upcoming 2019 Society for Neuro-Oncology (SNO) Annual Meeting on November 20-November 24 in Phoenix, Arizona
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top